Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.217001 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Letters, 2024. Verfasst von Kylie Fletcher und 36 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University School of Medicine, Nashville, USA. Electronic address: kylie.a.fletcher@vanderbilt.edu. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Institute, Associazione Italiana per la Ricerca sul Cancro, LUNGevity Foundation.
Abstract (Originalsprache)
Older patients have similar immune checkpoint inhibitor efficacy and rates of adverse events as younger patients, but appear to have decreased tolerability, particularly in the oldest patient cohort (>80 years), often leading to early cessation of therapy. We aimed to determine whether early discontinuation impacts efficacy of anti-PD-1 therapy in patients ≥80 years old. In this retrospective, multicenter, international cohort study, we examined 773 patients with 4 tumor types who were at least 80 years old and treated with anti-PD-1 therapy. We determined response rate, overall survival (OS), and progression-free survival (PFS) in patients who discontinued therapy early (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vanderbilt University School of Medicine, Nashville, USA. Electronic address: kylie.a.fletcher@vanderbilt.edu.
- Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128, Roma, Italy; Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperi…
- Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Vanderbilt University School of Medicine, Nashville, USA.
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
- Division of Hematology & Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Förderung
- National Cancer Institute
- Associazione Italiana per la Ricerca sul Cancro
- LUNGevity Foundation
- VANDERBILT UNIVERSITY
Zitieren
APA
Fletcher, K., Cortellini, A., Ganta, T., Kankaria, R., Song, H., Ye, F., Irlmeier, R., Debnath, N., Saeed, A., Radford, M., Alahmadi, A., Diamond, A., Hoimes, C., Presley, C. J., Owen, D. H., Abou Alaiwi, S., Nassar, A. H., Lamberti, G., Perrone, F., …, & Johnson, D. B. (2024). Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217001
Vancouver
Fletcher K, Cortellini A, Ganta T, Kankaria R, Song H, Ye F, et al. Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217001
BibTeX
@article{Fletcher2024,
author = {Fletcher, Kylie and Cortellini, Alessio and Ganta, Teja and Kankaria, Roma and Song, Haocan and Ye, Fei and Irlmeier, Rebecca and Debnath, Neha and Saeed, Anwaar and Radford, Maluki and Alahmadi, Asrar and Diamond, Akiva and Hoimes, Christopher and Presley, Carolyn J and Owen, Dwight H and Abou Alaiwi, Sarah and Nassar, Amin H and Lamberti, Giuseppe and Perrone, Fabiana and Buti, Sebastiano and Giusti, Raffaele and Filetti, Marco and Vanella, Vito and Mallardo, Domenico and Sussman, Tamara A and Galetta, Domenico and Kalofonou, Foteini and Daniels, Ella and Ascierto, Paolo A and Pinato, David J and Nebhan, Caroline and Berg, Stephanie and Choueiri, Toni K and Marron, Thomas U and Wang, Yinghong and Naqash, Abdul Rafeh and Johnson, Douglas B},
title = {Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.217001}
}
EUVIMED